Development of a Selective Modulator of Aryl Hydrocarbon (Ah) Receptor Activity that Exhibits Anti-Inflammatory Properties

Iain A. Murray,[†] Gowdahalli Krishnegowda,[‡] Brett C. DiNatale,[†] Colin Flaveny,[†] Chris Chiaro,[†] Jyh-Ming Lin,[§] Arun K. Sharma,[‡] Shantu Amin,[‡] and Gary H. Perdew^{*,†}

Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, Pennsylvania 16802, Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania 17033, and Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, Pennsylvania 17033

Received February 5, 2010

The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that mediates the toxicity of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. However, the role of the AHR in normal physiology is still an area of intense investigation. For example, this receptor plays an important role in certain immune responses. We have previously determined that the AHR can mediate repression of acute-phase genes in the liver. For this observation to be therapeutically useful, selective activation of the AHR would likely be necessary. Recently, the selective estrogen receptor ligand WAY-169916 has also been shown to be a selective AHR ligand. WAY-169916 can efficiently repress cytokine-mediated acute-phase gene expression (e.g., SAA1) yet fail to mediate a dioxin response element-driven increase in transcriptional activity. The goals of this study were to structurally modify WAY-169916 to block binding to the estrogen receptor and increase its affinity for the AHR. A number of WAY-169916 derivatives were synthesized and subjected to characterization as AHR ligands. The substitution of a key hydroxy group for a methoxy group ablates binding to the estrogen receptor and increases its affinity for the AHR. The compound 1-allyl-7-trifluoromethyl-1H-indazol-3-yl]-4-methoxyphenol (SGA 360), in particular, exhibited essentially no AHR agonist activity yet was able to repress cytokine-mediated SAA1 gene expression in Huh7 cells. SGA 360 was tested in a 12-O-tetradecanoylphorbol-13-acetate (TPA)-mediated ear inflammatory edema model using C57BL6/J and $Ahr^{-/-}$ mice. Our findings indicate that SGA 360 significantly inhibits TPAmediated ear swelling and induction of a number of inflammatory genes (e.g., Saa3, Cox2, and Il6) in C57BL6/J mice. In contrast, SGA 360 had no effect on TPA-mediated ear swelling or inflammatory gene expression in $Ahr^{-/-}$ mice. Collectively, these results indicate that SGA 360 is a selective Ah receptor modulator (SAhRM) that exhibits anti-inflammatory properties in vivo.

Introduction

An important aspect of systemic inflammation is the induction of an acute phase response in the liver. Circulating cytokines such as tumor necrosis factor- α (TNFA¹) or interleukin 1 β (IL1B) are elevated during sepsis or chronic inflammatory diseases. Inflammatory signaling within hepatocytes results in the induction of a series of genes that includes C-reactive protein, LPS binding protein, complement C3, tissue plasminogen activator, and serum amyloid A (SAA) (1). There are four members of this latter gene family in rodents, *Saa1* through 4, with *Saa1* and *Saa2* being the primary genes that contribute to the inducible circulating pool of SAA in serum. The induction of an acute phase response is generally believed to be an adaptive response in the short term that aids in the reaction to infection and other inflammatory insults. SAA has been suggested as an excellent marker for systemic inflammation, in part because up to a 1000-fold increase in transcription of these genes has been observed. However, recent studies of the biological activity of SAA suggest that it may also be a mediator of inflammation. SAA binds to FPRL1, RAGE, and TLR2 receptors; activation of these receptors leads to enhanced inflammatory signaling through activation of NFKB and AP1 (2–4). Prolonged production of SAA can lead to an array of adverse effects, such as accumulation of fibrils leading to amyloidosis (5). Therefore, repression of the acute phase response in the liver would be an important therapeutic target for a diverse array of chronic inflammatory diseases.

The AHR is a ligand activated basic-helix-loop-helix/Per-ARNT-Sim transcription factor that is responsible for the toxicity of TCDD (commonly referred to as dioxin). Upon ligand binding, the AHR, bound to hsp90, translocates into the nucleus where ARNT displaces hsp90 and heterodimerizes with the AHR (6). The ligand-bound AHR/ARNT complex is then able to bind to a dioxin responsive element (DRE) in the promoter of a wide range of genes involved in drug metabolism (e.g., *Cyp1a1*) as well as growth and metabolism (e.g., *Ereg, Snai2*). The physiological role of the AHR continues to be an active

^{*} To whom correspondence should be addressed. CMTC, 309 LSB, The Pennsylvania State University, University Park, PA. Phone: 814-865-0400. Fax: 814-863-1696. E-mail: ghp2@psu.edu.

[†] The Pennsylvania State University.

^{*} Department of Pharmacology, Penn State College of Medicine.

[§] Department of Biochemistry and Molecular Biology, Penn State College of Medicine.

¹ Abbreviations: TNFA, tumor necrosis factor-α; IL1B, interleukin 1 β ; SAA, serum amyloid A; NFKB, nuclear factor- κ B; AHR, Ah receptor; ARNT, AHR nuclear translocator; DRE, dioxin responsive element; CYP1A1, cytochrome P450 1A1; T_H1or T_H2, T lymphocyte helper type 1 and 2; SAhRM, selective AHR modulator; ER, estrogen receptor; THF, tetrahydrofuran; DMSO, dimethyl sulfoxide; TPA, 12-*O*-tetradecanoylphorbol-13-acetate; E₂, estradiol; TCDD, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin; GR, glucocorticoid receptor; α-NF, α-naphthoflavone.

area of investigation and was first explored through examination of the phenotype of Ahr null mice. These mice exhibit a number of defects, such as immune system dysfunction, poor liver vasculature development, and reduced fecundity (7). This latter phenotype appears to be due to multiple defects that result in lower conception rate, smaller litter size, and low pup survival rates (8). The lack of AHR expression alters maturation of follicles apparently due to a lack of estradiol synthesis (9). Cardiovascular effects, such as a systemic hypertension and hypoxemia conditions, have been observed in *Ahr* null mice, dependent on altitude (10).

Perhaps the area of AHR biology that has received the most recent attention is the ability of the AHR to influence T cell differentiation. The AHR can play a role in the balance of T_H1 and T_H2 cells, and this was established through the use of an AHR agonist M50367 that mediates a preference for increased $T_{\rm H}1$ versus $T_{\rm H}2$ cells (11, 12). M50367 exposure in mice leads to a decreased response in an allergic experimental model. Differentiation of naïve T-cells leads to enhanced AHR expression and supports the concept that the AHR mediates key steps in this process. Interleukin 17 (IL17)-producing T helper cells (Th17) are a proinflammatory subset of T helper cells that play a critical role in the experimental development of autoimmune diseases, such as collagen-induced arthritis (13). The AHR plays an important role in the development of Th17 cells in both in vitro and in vivo experimental models (14, 15). Furthermore, the AHR appears to regulate STAT1 activation during T cell differentiation into Th17 cells (16). How the AHR activation occurs under physiologic conditions is unknown, and whether these effects are mediated by endogenous ligands remains to be determined.

There are numerous reports indicating that prolonged activation of the AHR via exposure to high levels of an AHR agonist leads to enhanced inflammatory signaling (17). However, more recent studies have revealed that the AHR can mediate antiinflammatory responses as well, through interference with NFKB signaling or repression of IL6 induction (18, 19). We have recently demonstrated that the AHR can attenuate cytokinemediated induction of the acute phase response gene expression in the liver (20). This appears to be a selective response considering that the AHR fails to influence the induction of Il8 or Nfkbia. However, sustained activation of the AHR by xenobiotic agonists can lead to toxicity through a predominantly dioxin responsive element-mediated mechanism (21). Therefore, we tested the hypothesis that the AHR could be selectively activated by an appropriate ligand to repress cytokine-mediated induction of the acute phase response, yet fail to significantly induce gene expression through binding to its cognate response element. This goal was accomplished through the identification of the selective estrogen receptor ligand, WAY- 169916, as a selective² AHR modulator³ (SAhRM) (22). However, because of the dual AHR/estrogen receptor (ER) specificity of this compound, there is a need to find compounds that exhibit enhanced selectivity for the AHR. In this article, structure-activity studies were performed to modify the structure of WAY-169916 in order to enhance its affinity for the AHR and increase its AHR-mediated efficacy following modification. The following properties of the AHR were examined: to maintain SAhRM potential (i.e., mediate *Saa1* gene repression) in the absence of DRE-mediated signaling; to exhibit cross-species SAhRM activity; and to diminish or ablate ER binding status. One compound was synthesized, SGA 360, which met all of these criteria and proved useful in selectively modulating AHR activity in vivo.

Materials and Methods

Chemistry. Melting points were recorded on a Fischer-Johns melting point apparatus and are uncorrected. NMR spectra were recorded using a Bruker Avance 500 MHz spectrometer. Chemical shifts were recorded in ppm downfield from the internal standard. The signals are quoted as s (singlet), d (doublet), t (triplet), m (multiplet), and dt (doublet of triplet). MS analyses were run on a Hewlett-Packard Model 5988A instrument. Thin-layer chromatography (TLC) was developed on aluminum-supported precoated silica gel plates (EM industries, Gibbstown, NJ). Column chromatography was conducted on silica gel (60–200 mesh). The indazole derivatives were synthesized by following a previously described method with minor modifications (23) as detailed below.

Synthesis of 2-Fluoro-N-methoxy-N-methyl-3-(trifluoromethyl)benzamide (9). To a solution of 2-fluoro-3-(trifluoromethyl)benzoic acid (compound 6, 5.0 g, 24.02 mmol) in anhydrous tetrahydrofuran (THF) (100 mL) were added 2-chloro-4,6-dimethoxy-1,3,5-triazine (compound 7, 5.06 g, 28.81 mmol) and N-methylmorpholine (7.92 mL, 72.06 mmol). A white precipitate was formed at room temperature during 1 h of stirring, and then N,Odimethylhydroxylamine hydrochloride (2.5 g, 24.02 mmol) was added. The mixture was stirred at room temperature for an additional 8 h, quenched with water (50 mL), and extracted with ethyl acetate $(3 \times 100 \text{ mL})$. The combined organic layers were washed with saturated solution of sodium carbonate, followed by 1 N hydrochloric acid, and brine. The organic layer was dried over anhydrous sodium sulfate and evaporated in vacuo to yield 9 (5.2 g, 86%) as a viscous oil. ¹H NMR (500 MHz, CDCl₃) δ 7.72-7.31 (m, 3H), 3.56 (s, 3H), 3.39 (s, 3H); ESI-MS 252 $[M + H]^+$.

Synthesis of 2,4-Dimethoxyphenyl[(2-fluoro-3-(trifluoromethyl)phenyl]methanone (10). 2,4-Dimethoxyphenylmagnesium bromide (60 mL, 0.5 M in THF, 29.88 mmol) was added to a solution of compound 9 (2.5 g, 9.96 mmol) in anhydrous THF (50 mL) at 0 °C. The reaction mixture was stirred for 2 h at 0 °C and quenched with 5% hydrochloric acid in ethanol (20 mL). The solvents were removed under reduced pressure, extracted with ethyl acetate, washed with water, dried over anhydrous magnesium sulfate, and evaporated *in vacuo*. The crude product was purified by silica gel column chromatography, using ethyl acetate/hexanes (1:9) as eluent, to obtain 10 (2.6 g, 81%) as a white solid; mp 78–80 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.84–7.71 (m, 3H), 7.34 (t, 1H, J = 7.5 Hz), 6.61 (dd, 1H, J = 2.5 and 9.0 Hz), 6.46 (d, 1H, J = 2.5 Hz), 3.90 (s, 3H), 3.64 (s, 3H); ESI-MS 329 [M + H]⁺.

Synthesis of 3,4-Dimethoxyphenyl[(2-fluoro-3-(trifluoromethyl)phenyl]methanone (11). Following an identical procedure and purification as those described above for 10, we used 3,4dimethoxyphenylmagnesium bromide to give 11 (2.4 g, 75%) as a white solid; mp 101–103 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.79–7.82 (m, 1H), 7.71–7.74 (m, 1H), 7.57 (d, 1H, J = 2.0 Hz), 7.40 (t, 1H, J = 7.5 Hz), 7.30 (dt, 1H, J = 8.5 and 2.0 Hz), 6.91 (d, 1H, J = 8.5 Hz), 3.98 (s, 3H), 3.97 (s, 3H); ESI-MS 329 [M + H]⁺.

Synthesis of 3-(2,4-Dimethoxyphenyl)-7-(trifluoromethyl)-1*H*-indazole (12). To a solution of compound 10 (2.0 g, 6.09 mmol) in anhydrous pyridine (20 mL) was added anhydrous hydrazine (0.29 g, 9.0 mmol), and the reaction mixture was irradiated in a microwave apparatus for 1 h at 250 W and 100 °C. The solvent was evaporated under reduced pressure, extracted with ethyl acetate, washed with water, dried over anhydrous sodium sulfate, and concentrated to provide product 12 (1.85 g. 94%) as a white solid; mp 134–136 °C. ¹H NMR (500 MHz, DMSO- d_6) δ ,13.58 (s, 1H), 7.91 (d, 1H, J = 8.0 Hz), 7.74 (d, 1H, J = 7.5 Hz), 7.46 (d, 1H,

 $^{^2}$ The term selective is used to describe an AHR (or ER) ligand that exhibits a subset of altered transcriptional activities. The term is not used to infer that a given AHR ligand does not interact with other proteins.

³ A SAhRM is defined as an AHR ligand that is not capable of mediating a dioxin responsive element driven transcription yet is able to mediate other activities such as repression of cytokine mediated acute-phase gene expression.

J = 8.0 Hz), 7.27 (t, 1H, J = 7.5 Hz), 6.77 (d, 1H, J = 2.0 Hz), 6.69–6.66 (m, 1H), 3.86 (s, 3H), 3.80 (s, 3H); ESI-MS 322.9 [M + H]⁺.

Synthesis of 3-(3,4-Dimethoxyphenyl)-7-(trifluoromethyl)-1*H*-indazole (13). Microwave irradiation of compound 11 under conditions identical to those described above for 12 yielded product 13 (1.83 g, 93%) as a white solid; mp 175–177 °C. ¹H NMR (500 MHz, DMSO- d_6) δ 8.36 (d, 1H, J = 8.0 Hz), 7.80 (d, 1H, J = 7.0 Hz), 7.53 (dd, 1H, J = 8.0 and 2.0 Hz), 7.49 (d, 1H, J = 2.0 Hz), 7.37 (t, 1H, J = 7.5 Hz), 7.13 (d, 1H, J = 8.5 Hz), 3.88 (s, 3H), 3.84 (s, 3H); ESI-MS 322.9 [M + H]⁺.

Synthesis of 1-Allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (2) and 2-Allyl-3-(2,4-dimethoxyphenyl)-7-(trifluoromethyl)-2H-indazole (3). Sodium hydride (60% in oil, 0.21 g, 5.12 mmol) was added slowly to a solution of compound 12 (1.5 g, 4.66 mmol) in anhydrous N,N-dimethylformamide (15 mL) at room temperature. The reaction mixture was stirred for 30 min at ambient temperature to 60 °C. Allyl bromide (1.36 g, 11.26 mmol) was then added, and the reaction mixture was stirred for an additional 4 h at 60 °C. The mixture was poured into ice cold water, the solid product was separated by filtration, washed with water, and the isomers were purified by silica gel column chromatography eluting with 1% ethyl acetate in hexanes to provide products 2 and **3** as white solids. Product **2** [0.68 g (40%); mp 96–98 °C. ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta$ 7.88 (d, 1H, J = 8.0 Hz), 7.73 (d, 1H, J =7.0 Hz), 7.50–7.48 (m, 1H), 7.16 (t, 1H, J = 7.5 Hz), 6.63–6.61 (m, 2H), 6.13-6.08 (m, 1H), 5.19 (d, 2H, J = 11.5 Hz), 5.16 (dd, 1H, J = 6.5 and 8.0 Hz), 5.06 (dd, 1H, J = 1.5 and 17 Hz), 3.87 (s, 3H), 3.80 (s, 3H)]; ESI-MS 363 $[M + H]^+$. Product **3** [0.51 g (30%); mp 73–75 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.60 (d, 2H, J = 7.5 Hz), 7.22 (d, 1H, J = 8 Hz), 7.05 (t, 1H, J = 7.5 Hz), 6.65-6.61 (m, 2H), 6.05-5.99 (m, 1H), 5.11 (dd, 1H, J = 1.5 and10 Hz), 5.02-4.92 (m, 3H), 3.90 (s, 3H), 3.75 (s, 3H)]; ESI-MS $363 [M + H]^+$

Synthesis of 1-Allyl-3-(3,4-dimethoxyphenyl)-7-(trifluoromethyl)-1H-indazole (4) and 2-Allyl-3-(3,4-dimethoxyphenyl)-7-(trifluoromethyl)-2H-indazole (14). Subjecting compound 13 to reaction conditions identical to those described above for compound 12 in the synthesis of 2 and 3, yielded products 4 and 14 as white solids. Product 4 [0.76 g (45%), viscous oil]. ¹H NMR (500 MHz, CDCl₃) δ 8.21 (d, 1H, J = 7.5 Hz), 7.80 (d, 1H, J = 7.5 Hz), 7.47-7.44 (m, 2H), 7.27 (t, 1H, J = 7.5 Hz), 7.04 (d, 1H, J = 8.0Hz), 6.16-6.09 (m, 1H), 5.25-5.23 (m, 2H), 5.21 (dd, 1H, J = 10.5 and 1.5 Hz), 5.07 (dd, 1H, J = 17.0 and 1.5 Hz), 4.02 (s, 3H), 3.98 (s, 3H)]; ESI-MS 363 [M + H]⁺. Product 14 [0.56 g (33%); mp 86-88 °C. ¹H NMR (500 MHz, CDCl₃) δ 7.77 (d, 1H, J = 8.5 Hz), 7.67 (d, 1H, J = 7.0 Hz), 7.15–7.10 (m, 2H), 7.06 (d, 1H, J = 8.5 Hz), 7.03 (d, 1H, J = 2.0 Hz), 6.23-6.14 (m, 1H),5.28 (dd, 1H, J = 10.0 and 1.0 Hz), 5.13–5.11 (m, 2H), 5.06 (dd, 1H, J = 17.5 and 1.0 Hz), 4.01 (s, 3H), 3.93 (s, 3H)]; ESI-MS 363 $[M + H]^+$.

Synthesis of 4-[1-Allyl-7-trifluoromethyl-1H-indazol-3-yl]benzene-1,3-diol (1). To a solution of compound 8 (0.5 g, 0.38 mmol) in 5 mL of methylene chloride/cyclohexane (6:1) was added boron tribromide (1.0 M in methylene chloride, 11.02 mL, 11.04 mmol) at -30 °C. The reaction was allowed to warm to room temperature over 5 h. The reaction was quenched with 2 mL of methanol and diluted with methylene chloride. The organic phases were washed with saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 1% methanol in methylene chloride to obtain product 10 (210 mg, 45%) as a white solid; mp 113-115 °C). ¹H NMR (500 MHz, acetone-d₆) δ 8.55 (d, 1H, J = 8.5 Hz), 7.96 (d, 1H, J = 7.5 Hz), 7.93 (d, 1H, J = 8.5 Hz), 7.44 (t, 1H, J = 8 Hz), 6.57 (dd, 1H, J = 2.5 and 8.5 Hz), 6.54(d, 1H, J = 2.5 Hz), 6.16-6.09 (m, 1H), 5.23-5.18 (m, 3H),5.05 (dd, 1H, J = 1.5 and 17 Hz); ESI-MS 335 $[M + H]^+$

Synthesis of 2-[1-Allyl-7-trifluoromethyl-1*H*-indazol-3-yl]-4methoxyphenol (5). Following an identical procedure and purification as those described above for 1, except for using 1 equiv (0.38 mmol) boron tribromide gave 5 (0.22 g, 47%) as a white solid; mp 52–54 °C. ¹H NMR (500 MHz, acetone- d_{δ}) δ 8.59 (d, 1H, J = 8.5 Hz), 8.03 (d, 1H, J = 8.5 Hz), 7.99 (d, 1H, J = 7.5 Hz), 7.47 (t, 1H, J = 8.0 Hz), 6.68 (dd, 1H, J = 8.5 and 2.5 Hz), 6.64 (d, 1H, J = 2.5 Hz), 6.21–6.12 (m, 1H), 5.27 (d, 1H, J = 5.5 Hz), 5.23 (dd, 1H, J = 10.5 and 1.0 Hz), 5.07 (dd, 1H, J = 17.0 and 1.0 Hz), 3.87 (s, 3H)]; ESI-MS 349 [M + H]⁺.

Biology. ERa Competition Assay. The ER- α Competitor Assay, Green (Invitrogen) was performed following the manufacturer's instructions. Briefly, compounds and DMSO vehicle were diluted to twice their final assay concentrations in PanVera supplied ES2 screening buffer and added to 60×150 mm borosilicate glass cell culture tubes. A master mix was made of screening buffer with human recombinant ER α added, for a final concentration of 6 pmol/ μ L, and ES2 fluoromone added, for a final concentration of 400 nM. The master mix was added to diluted test compounds in a 1:1 volume, mixed gently, and incubated in the dark at room temperature for 2 h. Samples were then measured for fluorescence polarization using the PanVera Beacon 2000 polarization instrument with 485 nm excitation and 530 nm emission filters at 25 °C. Results shown are the mean of samples performed in triplicate.

Cell Culture. All cell lines utilized except for MCF-7 cells were maintained in modified Eagle's α -minimum essential medium (Sigma), supplemented with 1000 units/mL penicillin, 100 μ g/mL streptomycin (Sigma), and 8% fetal bovine serum (Hyclone) under standard conditions. Huh 7 cells were obtained from Curt Omiecinski (Penn State University). MCF-7 cells were obtained from ATCC.

Cell-Based Luciferase Reporter Assays. The DRE-driven luciferase reporter cell lines, human HepG2 40/6 and mouse H1L1.1c2, were used to assess AHR transcriptional activity (24, 25). The latter cell line was kindly provided by Michael Denison (University of California, Davis). Luciferase activity was measured using the Promega Luciferase Assay system (Madison, WI).

Quantitation of mRNA Levels. Total RNA was isolated from cells using TRI reagent (Sigma) following the manufacturer's standard protocol and converted to cDNA using High Capacity cDNA Archive Kit from Applied Biosystems. The levels of CYP1A1 and SAA1 were determined by real-time qPCR using iQ SYBR Green supermix reagent (BioRad) and a MyIQ single-color PCR detection system (Bio-Rad). Primer sequences utilized have been previously described or are listed below (19). PCR primers (Integrated DNA Technologies, Coralville, IA) used in this study are as follows human L13a (forward) CCTGGAGGAGAAGAGAGAAGAGAA and human L13a (reverse) GAGGACCTCTGTGTATTTGTCAA; human SAA1 (forward) AGGCTCAGACAAATACTTCCATGC and human SAA1 (reverse) TCTCTGGCATCGCTGATCACTTCT; human CYP1A1 (forward) TCTTCCTTCGTCCCCTTCAC and human CYP1A1 (reverse) TGGTTGATCTGCCACTGGTT; mouse *Illb* (forward) ATACTGCCTGCCTGAAGCTCTTGT and mouse *Illb* (reverse) AAGGGCTGCTTCCAAACCTTTGAC; mouse Saa3 (forward) ATGCCAGAGAGGCTGTCCAGAAGT and mouse Saa3 (reverse) TATCTTTTAGGCAGGCCAGCAGGT; mouse L13a (forward) TTCGGCTGAAGCCTACCAGAAAGT and mouse L13a (reverse) GCATCTTGGCCTTTTTCCGTT; mouse Cox2 (forward) TTGCTGTACAAGCAGTGGCAAAGG and mouse Cox2 (reverse) TGCAGCCATTTCCTTCTCTCTGT; mouse *Il10* (forward) TGAATTCCCTGGGTGAGAAGCTGA and mouse *Il10* (reverse) TGGCCTTGTAGACACCTTCCTCTT. In all cases, melting point analysis revealed the amplification of a single product. Data acquisition and analysis were achieved using MyIQ software (Bio-Rad, Hercules, CA). Quantification was achieved through comparison against target-specific standard curves, and data represent the mean fluorescence normalized to that of the control gene ribosomal protein L13a to yield a relative mRNA level.

AHR Competition Binding Assay. The AHR photoaffinity ligand 2-azido-3-[¹²⁵I]-7,8-dibenzo-*p*-dioxin was synthesized as described (26). Liver cytosolic extract from B6.Cg-Ahr^{tm1Bra}Tg (Albcre, Ttr-AHR)1Ghp (expressing the human AHR in hepatocytes) was utilized in a photoaffinity ligand competition binding assay as previously described (27, 28).

Scheme 1. Synthesis of Indazole Derivatives^a



^{*a*} Reagents and conditions: (i) *N*-methylmorpholine, THF, RT, 1 h; (ii) *N*,*O*-dimethylhydroxylamine hydrochloride, RT, 8 h; (iii) 2,4-dimethoxyphenylmagnesium bromide, THF, 0 °C, 2 h; (iv) 3,4-dimethoxyphenylmagnesium bromide, THF, 0 °C, 2 h; (v) anhydrous H₂NNH₂, pyridine, microwave, 250W, 100 °C, 1 h; (vi) NaH, DMF, RT to 60 °C, 30 min, allyl bromide, 60 °C, 4 h; (vii) 1 equiv BBr₃, CH₂Cl₂/cyclohexane, -60 °C to RT, 5 h; (viii) 1 equiv BBr₃, CH₂Cl₂/cyclohexane, -60 °C to RT, 5 h.

Electrophoretic Mobility Shift Assay (EMSA). DRE-specific EMSAs were performed using in vitro translated human AHR and ARNT as previously described (28).

SAA Repression Assay. Huh7 cells were treated with SGA compounds for 1 h prior to the addition of 2 ng/mL of IL1B for 6 h. RNA was isolated and *SAA1* mRNA levels determined as previously described (*20*).

In Vivo Ear Edema Model. Ear inflammation was induced in anesthetized 6 week-old male C57BL6/J mice (wild-type or Ahr^{-/-} through topical application of 1.5 μ g of 12-O-tetradecanoylphorbol-13-acetate (TPA) in 50 μ L of vehicle (HPLC-grade acetone) (Sigma) to the right ear. Anti-inflammatory properties of SGA 360 were examined through topical application of 30 μ g of SGA 360 in 50 μ L of vehicle immediately followed by the administration of TPA. In all cases, the left ear received the vehicle alone. Six hours after the induction of inflammation, animals were euthanized by carbon dioxide asphyxiation, and the degree of inflammation was assessed. Edema thickness was measured using a micrometer, and edema weight was determined following the isolation of a 7 mm ear punch. Total RNA was isolated from ear punches, and RNA concentration was determined via spectrophotometry at λ 260 and 280 nm. Total RNA was reverse transcribed to cDNA using High Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA).

Statistical Analysis. One-way ANOVA was followed by Tukey's multiple comparison test and was used to compare treatments using GraphPad Prism v5.0.

Results

Synthesis of Indazole Derivatives. The synthesis of indazole derivatives 1–5 was carried out as outlined in Scheme 1. Amide 9 was synthesized from 2-fluoro-3-(trifluoromethyl)benzoic acid following literature methods (29, 30). Conversion of compound 9 to benzophenone derivative 10 was accomplished by treating

it with 2,4-dimethoxyphenylmagnesium bromide. Microwave irradiation of **10** in the presence of anhydrous hydrazine gave an excellent yield (94%) of compound **12**, which, on treatment with allyl bromide in the presence of sodium hydride, resulted in a mixture of desired indazole derivatives **2** and **3**. A similar reaction sequence led to the formation of a mixture of compounds **4** and **14**. The two isomers in each case were separated by silica gel column chromatography. Compound **1** (WAY-169916) was obtained by treating compound **2** with excess of boron tribromide, while selective demethylation of **2** using 1 equiv of boron tribromide led to an exclusive formation of monohydroxy derivative **5**.

The structures of 1-allyl and 2-allyl substituted isomers 4 and 14 are similar and cannot be determined by proton NMR spectra analysis alone (Figures S1 and S2, Supporting Information). Therefore, each proton was assigned on the basis of the coupling pattern and ¹H-¹H COSY spectra. All of the carbon atoms were assigned with the aid of HSQC experiments and the coupling between the fluorine of the trifluoromethyl group and C_7 , and C_6 with its distinguished quartet pattern and coupling constant. The tertiary carbons assignment was determined with the help of HMBC experiments. In order to determine the position of the allyl substitution, we measured the possible NOE effects between the allyl protons and dimethoxyphenyl group, but the results were not conclusive. The position of the allyl substitution was verified by HMBC experiments. The assignment of these two isomers is listed in Tables 1 and 2. We observed that the H₁₀ proton at the 2-allyl group interacted with C₁₁, C₁₂, and C₃ carbons (Figure S3, Supporting Information). However, the H₁₀ proton at the 1-allyl substitution did not couple with the C₃ carbon but interacted with C11, C12, and C8 carbons (Figure S4,

Ah Receptor Selective Ligand Inhibits Inflammation

$Fable 1.^{-1}$	H and ¹	¹³ C Assignments	of 1-All	vl-3-(3,4-0	dimethoxypl	henvl)-7-	(trifluoromethy	I)-1 <i>H</i> -indazole
		e -		• \ /		• /		/

proton assignment					carbon-13 assignment			
proton ^a	chemical shift δ (ppm)	multi	coupling constant	C-13 ^b	chemical shift δ (ppm)	coupling constant		
H ₃	N/A	N/A	N/A	C_3	124.8			
H_4	8.19	d, 1H	$J = 7.40 \; \text{Hz}$	C_4	125.35			
H_5	7.28	t, 1H	$J = 7.40 \; \text{Hz}$	C ₅	119.69			
H ₆	7.79	d, 1H	$J = 7.40 \; \text{Hz}$	C_6	125.42	q, $J = 6.16 \text{ Hz}$		
				C_7	112.75	q, $J = 32.75 \text{ Hz}$		
				C_8	136.32			
				C_9	145.62			
				CF3	123.95	q, J = 272.09 Hz		
Allyl Group								
H_{10}	5.25	br d, 2H	J = 5.12 Hz	C_{10}	53.45			
H_{11}	6.17-6.09	m, 1H		C ₁₁	133.48			
H_{12}	5.21	dd,1H	J = 10.5 Hz; $J = 1.3$ Hz;	C ₁₂	116.9			
H _{12'}	5.07	dd, 1H	J = 17.3 Hz; J = 1.3 Hz					
Phenyl Group								
$H_{1'}$	N/A	N/A	N/A	$C_{1'}$	124.61			
$H_{2'}$	7.44	d, 1H	$J = 1.95 \; \text{Hz}$	C _{2'}	111.11			
$H_{3'}$	N/A	N/A	N/A	C _{3'}	149.48			
$H_{4'}$	N/A	N/A	N/A	$C_{4'}$	149.39			
H _{5'}	7.04	d, 1H	J = 8.05 Hz	C5'	111.34			
$H_{6'}$	7.45	dd, 1H	J = 8.05 Hz; J = 1.95 Hz	C _{6'}	120.61			
3'-OMe	3.99	s, 3H		3'-OMe	56.02			
4'-OMe	4.01	s, 3H		4'-OMe	56.06			

^a Proton NMR was measured at 500 MHz with CDCl₃ as the solvent. ^{b 13}C NMR was measured at 125 MHz with CDCl₃ as the solvent.

proton assignment				carbon-13 assignment					
proton ^a	chemical shift δ (ppm)	multi.	coupling constant	C-13 ^b	chemical shift δ (ppm)	coupling constant			
H ₃	N/A	N/A	N/A	C ₃	137.03				
H_4	7.78	d, 1H	J = 8.33 Hz	C_4	125.05				
H_5	7.14	br t, 1H	$J = 7.76 \; \text{Hz}$	C_5	120.09				
H_6	7.66	dt, 1H	J = 7.04 Hz; $J = 0.90$ Hz	C_6	124.63	q, $J = 5.19 \text{ Hz}$			
				C_7	118.57	q, J = 32.7 Hz			
				C_8	143.5	-			
				C_9	122.5				
				CF ₃	124.06	q, <i>J</i> = 273.5 Hz			
	Allyl Group								
H_{10}	5.12	dt, 2H	J = 5.03 Hz; $J = 1.53$ Hz	C^{10}	53.49				
H ₁₁	6.23-6.15	m, 1H		C ₁₁	133.43				
H ₁₂	5.28	dq, 1H	J = 10.29 Hz; $J = 1.02$ Hz	C ₁₂	117.9				
H _{12′}	5.06	dq, 1H	J = 17.29 Hz; $J = 1.31$ Hz						
Phenyl Group									
$H_{1'}$	N/A	N/A	N/A	$C_{1'}$	121.21				
$H_{2'}$	7.03	d, 1H	$J = 1.9 \; {\rm Hz}$	$C_{2'}$	112.57				
$H_{3'}$	N/A	N/A	N/A	C _{3'}	149.94				
$H_{4'}$	N/A	N/A	N/A	$C_{4'}$	149.28				
H _{5'}	7.07	dd, 1H	J = 8.35 Hz; $J = 1.9$ Hz	C _{5'}	111.48				
H _{6'}	7.11	d, 1H	J = 8.35 Hz; $J = 1.9$ Hz	C _{6'}	122.56				
3'-OMe	3.93	s, 3H		3'-OMe	56.04				
4'-OMe	4.00	s, 3H		4'-OMe	56.09				

Table 2. ¹H and ¹³C Assignments of 2-Allyl-3-(3,4-dimethoxyphenyl)-7-(trifluoromethyl)-1*H*-indazole

^a Proton NMR was measured at 500 MHz with CDCl₃ as the solvent. ^{b 13}C NMR was measured at 125 MHz with CDCl₃ as the solvent.

Supporting Information). These long-range ${}^{1}H^{-13}C$ couplings provide direct evidence to support our assignment.

Structural Modification of WAY-169916 Blocks Estrogen Receptor Binding and Fails to Influence ER-Mediated Transcriptional Activity. In a previous study, we have demonstrated that WAY-169916 (1) is a selective activator of the AHR (22). However, WAY-169916 is also a potent selective ligand for the estrogen receptor (31). We hypothesized that alteration of a critical hydroxyl group in the para position of the phenyl ring to a methoxy group on the benzene ring would result in greatly reduced affinity for the ER and enhanced affinity for the AHR. To achieve this goal and to perform a structure activity study that would focus on making an effective selective AHR ligand, four derivatives of WAY-169916 were synthesized (Figure 1). WAY-169916, SGA 293, 315, and 360 were subjected to an ER α competition assay that measures the ability of a compound to displace a fluorescent ER ligand. Fluoromone bound to the ER tumbles slowly in solution, giving a higher polarization reading (mP). Compounds that compete with the fluoromone away from the ER result in free fluoromone that tumbles faster and provide a lower mP value. Nonspecific binding effects can be seen by the shift of mP from ER α and fluoromone alone to the addition of 1% DMSO in the reaction (roughly 10% drop in mP). The addition of estradiol (E₂) at higher concentrations displaces the fluoromone and represents maximum competition (Figure 2A). SGA 293, 315, and 360 show minimal ER α competition at 10 μ M doses, less than that of 1 nM E₂. Only WAY-169916 demonstrated a highly significant level of binding to the ER α . The marginal level of binding observed with SGA 360 was explored further through



Figure 1. Structures of indazole derivatives; compounds 1 (WAY-169916); 2 (SGA 293); 3 (SGA 294); 4 (SGA 360); and 5 (SGA 315).



Figure 2. Structural modification of WAY-169916 blocks binding to the estrogen receptor. (A) Estrogen receptor α fluorescence polarization assays were performed on each SGA compound. (B) A dose-response estrogen receptor α fluorescence polarization assay experiment was performed on SGA 360. (C) Estrogen receptor β fluorescence polarization assays were performed.

a dose–response experiment (Figure 2B). SGA 360 failed to exhibit a dose dependent decrease in polarization, with 10 nM and 10 μ M yielding the same level of inhibition. Furthermore,



Figure 3. Assessment of AHR agonist or antagonist transcriptional activity in human cells mediated by the SGA compounds. (A) HepG2 40/6 stable reporter cell line was treated with 2 nM TCDD or 10 μ M of each SGA compound for 4 h, and the cells were lysed and DRE-driven luciferase activity determined. (B) HepG2 40/6 cells were treated as indicated for 4 h, RNA was isolated, and *CYP1A1* and *rL13a* mRNA levels were determined using real-time RT-PCR. (C) Co-treatment of HepG2 40/6 cells with SGA compounds and 2 nM TCDD for 4 h followed by measurement of luciferase activity. Data represent the mean \pm SEM. Statistically significant changes that are marked with an asterisk are relative to the control (n = 3/treatment group; * P < 0.05).

the addition of SGA 360 to the assay in the absence of ER resulted in a modest level of inhibition in the assay (Figure S5, Supporting Information). Whether SGA 360 can bind to ER β was also tested; while both WAY-169916 and E2 exhibited a marked level of binding, SGA 360 failed to bind to ER β (Figure 2C). This would indicate that SGA 360 is not a ligand for the estrogen receptor.

Since SGA 360 is a derivative of a selective ER ligand, we wanted to test whether SGA 360 could act as an ER antagonist and block E2 mediated induction of the progesterone receptor B gene, an ER target gene. MCF-7 cells were treated with E2 in the presence or absence of SGA 360 for 4 h and the level of progesterone receptor B mRNA assessed. The results indicate that SGA 360 has no statistically significant effect of the induction of progesterone receptor B gene expression (Figure S6, Supporting Information).

SGA Compounds Fail to Stimulate AHR-Dependent DRE-Mediated Transcription Activity and Exhibit Antagonist⁴ Activity. The ability of the SGA compounds to induce AHR-mediated agonist activity was tested in the HepG2 40/6 cell line, which contains a stably integrated DRE-driven luciferase vector. None of the SGA compounds tested displayed a significant level of reporter activity (Figure 3A). The ability of SGA compounds to induce *CYP1A1* transcription in Hep G2 40/6 cells was also assessed through quantitative PCR (Figure 3B). Interestingly, SGA 293, WAY-169916, and SGA 360 actually repressed constitutive *CYP1A1* expression. In contrast, SGA 315 induced a significant increase in *CYP1A1* mRNA levels, although considerably lower than 10 nM TCDD. Next,

⁴ An AHR antagonist is an AHR ligand that is not capable of inducing AHR mediated activities.



Figure 4. Assessment of AHR-driven transcriptional activity in a mouse reporter cell line mediated by the SGA compounds. H1L1.1c2 cells were treated with 1 nM TCDD or 10 μ M of each SGA compound for 4 h, and cells were lysed and DRE-driven luciferase activity determined.



Figure 5. SGA 315 is capable of activating AHR/ARNT DNA binding in an EMSA. Each SGA compound was tested for its ability to induce AHR/ARNT binding to a DRE containing oligonucleotide. The AHR agonist β -naphthoflavone (β -NF) was utilized as a positive control.

the ability of these compounds to antagonize AHR agonist mediated transcriptional activity was assessed using the HepG2 40/6 reporter cell line. In a dose dependent manner, all SGA compounds were capable of attenuating TCDD-mediated induction of luciferase activity (Figure 3C), with SGA 315 exhibiting the highest level of competition. In the literature, certain AHR ligands have exhibited species selectivity in their ability to behave as AHR agonists (32). If studies are to be performed using these compounds in vivo, their ability to regulate AHR activity needs to be explored in rodent cell lines. Therefore, we tested the ability of the SGA compounds to exhibit agonist activity in Hepa 1.1 cells (Figure 4). SGA 315 was capable of inducing significant agonist activity as observed in Hep G2 cells. Several of the SGA compounds appear to exhibit antagonistic activity, blocking the ability of an agonist to mediate transactivation of Cyp1a1. Such antagonism could occur through three distinct mechanisms, the first being the mediation of AHR/ ARNT heterodimer formation and subsequent binding to a DRE, without any increase in gene transcription. The second possibility is that they are not capable of inducing heterodimer formation. The third mechanism is mediating heterodimer formation that fails to bind to a DRE. To examine this issue further, an EMSA was performed with the SGA compounds, and only SGA 315 was capable to significantly induce AHR binding to a DRE (Figure 5). This would indicate that SGA 293, 294, and 360 are not able to facilitate AHR/ARNT dimerization capable of binding to a DRE.

SGA Compounds Are Direct Ligands for the AHR. In order to demonstrate that SGA compounds directly interact with the ligand-binding pocket of the AHR, a competition binding



Figure 6. SGA compounds vary in their ability to compete with the photoaffinity ligand in a competition AHR binding assay. Increasing amounts of the compounds labeled in each graph were added to mouse liver cytosol expressing the human AHR in the presence of the photoaffinity ligand (420 pM). After exposure to UV light, samples were subjected to tricine SDS–PAGE and transferred to the membrane, and radioactive bands were excised and counted in a γ counter.

assay was used. This assay utilizes the photoaffinity ligand, 2-azido-3-[¹²⁵I]iodo-7,8-dibenzo-*p*-dioxin, in the presence or absence of a competitor ligand. Each SGA compound tested effectively competed with the photoaffinity ligand (Figure 6). Both SGA 315 and SGA 360 exhibited a much greater ability to compete for AHR binding sites than WAY-169916, suggesting a higher affinity for the AHR relative to the parent compound.

SGA Compounds Repress Cytokine-Mediated SAA1 Induction in an AHR-Dependent Manner. We have recently demonstrated that WAY-169916 is capable of repressing SAA1 induction in Huh7 cells in an AHR-dependent manner (22). Huh7 cells were treated with SGA compounds for 1 h prior to exposure to IL1B for 3 h. Each SGA compound at a 10 μ M concentration was tested in this assay, and all were found to repress IL1B-mediated induction of SAA1 (Figure 7). SGA 315, which exhibits some agonist activity, yielded the greatest level of repression.

SAhRM SGA360 Exhibits Anti-Inflammatory Activity in Vivo. The cell culture-based data assessing the antiinflammatory properties of the putative SAhRM SGA360 clearly suggest the capacity of SGA360 to suppress inflammatory *SAA1* signaling in an AHR-dependent manner through a mechanism that does not require AHR binding to its cognate response

Murray et al.



Figure 7. All of the SGA compounds are able to inhibit IL1Bmediated *SAA1* gene expression. Huh7 cells were pretreated with each SGA compound for 1 h prior to the addition of 2 ng/mL IL1B. After 3 h, RNA was isolated and the level of *SAA1* and *rL13a* mRNA determined. Data represent the mean \pm SEM. Statistically significant changes that are marked with an asterisk are relative to IL1B treatment alone (n = 3/treatment group; * P < 0.05; ** P < 0.01; *** P < 0.001).

element; consequently, SGA360 fulfills the criteria of a SAhRM under cell culture conditions. While cell culture data is informative, it is descriptive of the effect in an isolated and homogeneous cell population and may not accurately convey an in vivo physiological response. Therefore, we further investigated the anti-inflammatory activity of SGA360 in an in vivo murine model of inflammation. The phorbol ester (TPA)-induced ear edema model is a well established model utilized to examine the anti-inflammatory efficacy of test substances and was used here to determine the capacity of SGA360 to suppress inflammatory responses. Six week old male C57/B6J mice (wild-type or Ahr $^{-/-}$) were exposed to 1.5 μ g of TPA or 30 μ g of SGA360 in combination with TPA through topical application to the right ear, while the left ear received the vehicle (acetone) alone. Following 6 h of exposure, the degree of TPA-induced inflammation and the effect of SGA360 were assessed by edema quantification and quantitative PCR (Figures 8 and 9). Physical measurement of ear thickness and the wet weight of 7 mm ear punches (Figure 8A) revealed that 6 h of topical exposure to 1.5 μ g of TPA is sufficient to evoke a marked inflammatory response and subsequent edema. Exposure to SGA360 im-



Figure 8. SGA360 exhibits anti-inflammatory properties in vivo. Ear inflammation was induced in anesthetized 6-week-old male C57/B6J mice (wild-type or $Ahr^{-/-}$) through topical application of 1.5 μ g of TPA in 50 μ L of vehicle (acetone) to the right ear. Anti-inflammatory properties of SGA360 were examined through topical application of 30 μ g of SGA360 in 50 μ L of vehicle immediately followed by the administration of TPA. In all cases, the left ear received vehicle alone. The degree of inflammation was assessed after 6 h by measuring ear edema thickness using a micrometer and ear edema wet weight following the removal of a 7 mm diameter ear punch. Data represent (A) mean edema thickness (mm) and mean edema weight (mg) \pm SEM. (B) Mean percentage change in edema thickness and weight relative to vehicle-treated \pm SEM (n = 3/treatment group; * P < 0.05; ** P < 0.01; *** P < 0.001).



Figure 9. SGA 360 suppressed inflammatory gene expression in vivo. Ear inflammation was induced in anesthetized 6-week-old male C57/ B6J mice (wild-type or $Ahr^{-/-}$) through topical application of 1.5 µg of TPA in 50 µL of vehicle (acetone) to the right ear. Anti-inflammatory properties of SGA 360 were examined through the topical application of 30 µg of SGA 360 in 50 µL of vehicle prior to the administration of TPA. In all cases, the left ear received the vehicle alone. Changes in inflammatory gene expression were assessed through quantitative PCR using primers targeted against *Cox2*, *Il6*, *Il1b*, *Saa3*, and *Il10*. Data represent the mean mRNA levels normalized to constitutive ribosomal protein *L13* mRNA expression \pm SEM (n = 3/treatment group; * P < 0.05; ** P < 0.01; *** P < 0.001).

mediately prior to the administration of TPA significantly diminished both of these inflammatory indicators in wild-type mice by ~50% (Figure 8B). Exposure to SGA360 alone was indistinguishable from the vehicle-treated mice regarding ear thickness and weight (data not shown). Contrary to the anti-inflammatory effect of SGA360 observed in wild-type animals, exposure of $Ahr^{-/-}$ animals to SGA360 and TPA revealed no significant decrease in either edema thickness or wet weight, thus indicating a requirement for AHR expression to mediate the inhibitory effect of SGA360 on TPA-induced edema.

The observed in vivo diminishment of physical edema parameters by SGA360 prompted us to examine the effect of SGA360 upon pro-inflammatory gene expression. Using RNA isolated from ear punches taken from animals exposed to the vehicle, TPA, and SGA360/TPA, the mRNA expression levels of cyclooxygenase-2 (*Cox2*), interleukin 6 (*Il6*), interleukin 1β (II1b), serum amyloid-associated-3 (Saa3), and interleukin 10 (1110) were examined by quantitative PCR (Figure 9). Exposure of C57BL6/J mice to TPA for 6 h stimulated the expression of all gene targets examined relative to the vehicle-treated controls, consistent with the appearance of edema. Application of SGA360 immediately prior to TPA resulted in a significant suppression of inflammatory gene expression. Cox2 mRNA was reduced to near basal levels, while Il6, IL1b, Saa3, and Il10 were repressed by 70, 70, 90, and 75%, respectively, relative to that of TPA treatment alone. In contrast, Ahr^{-/-} mice under the same treatment regime failed to demonstrate any significant repression of the same inflammatory gene targets relative to that of the TPA-treated animals alone (Figure 9). Interestingly, with the exception of Saa3, the basal and TPA-induced levels of the inflammatory gene targets were lower in $Ahr^{-/-}$ mice than in their wild-type counterparts and thus consistent with the slightly diminished onset of edema observed with $Ahr^{-/-}$ animals. Such data demonstrates that the SAhRM SGA360 has in vivo anti-inflammatory activity and emphasizes a requirement of AHR to facilitate such potential.

Discussion

There are basically two types of selective nuclear receptor ligands, the first class are ligands that induce receptor dimerization, subsequently binding to their cognate response element and mediating selective recruitment of coactivators/corepressors. The second type of selective ligand induces dimerization but fails to elicit binding to its response element. An example of the latter is the identification of a selective glucocorticoid receptor (GR) ligand (33). The discovery of selective GR ligands (e.g., ZK 216348), in theory, could result in repression of inflammation without many of the side effects of classical GR activators. Studies with the estrogen receptor (ER) have developed highly selective ligands that bind to the receptor and selectively activate nuclear binding to other transcription factors such as NFKB (23). In contrast, these ligands fail to induce estrogen response element driven gene expression or estradiolmediated physiological effects, such as uterine weight gain (31). One such ER selective ligand, WAY-169916, can effectively inhibit the progression of rheumatoid arthritis in a rat model system and inhibit inflammatory bowel disease in a transgenic rat model (31, 34). The same line of reasoning used in these studies was pursued in the development of selective AHR ligands. However, as a bHLH-PAS protein the AHR has a markedly different arrangement of functional domains compared to nuclear receptors and thus may not be as amenable to being selectively activated. For example, the AF2 transactivation domain and ligand binding pocket are in close proximity in nuclear receptors. In contrast, the transactivation and ligand binding domains appear to be distinct regions in the AHR. Whether the binding of a ligand to the AHR can influence coactivator recruitment or AHR/ARNT DNA-binding is less certain. In a recent study, we have shown that WAY-166916 is both a selective estrogen and Ah receptor ligand, with higher affinity for the estrogen receptor (22). A series of studies with WAY-169916 have revealed that it exhibits minimal AHR agonist activity yet is efficient at repressing acute phase gene expression. WAY-169916 can be classified as a SAhRM, yet its ability to act as a selective ligand for the ER limits its usefulness in terms of studying AHR function. The goal of this study was to develop a derivative of WAY-169916 that fails to bind to the ER and exhibits greater affinity for the AHR. The cocrystal structure of WAY-169916 occupying the estrogen receptor ligand binding pocket reveals that the phenol of WAY-169916 interacts with Glu-353 and Arg-394, and this interaction is believed to be a key component of its high affinity for the estrogen receptor (23). This notion, coupled with the concept that polar groups usually decrease the affinity of ligands for the AHR, lead to examining the effects of substituting methoxy groups for hydroxyl groups in WAY-169916. The replacement of one or two hydroxyl groups with methoxy groups leads to almost total loss of estrogen receptor binding for SGA 315, 293, and 360 (Figure 2). In order to be considered a SAhRM, the SGA compound needed to exhibit a lack of agonist activity in both mouse and human reporter cell lines. Both SGA 293 and SGA 360 would meet this criterion, in contrast SGA 315 and 294 exhibited a statistically significant increase in AHRmediated reporter activity in cells. Furthermore, SGA 293 and SGA 360 exhibited potential similar to that of repressed cytokine-mediated induction of SAA1 gene expression. Examination of the relative affinity of each SGA compound in an AHR competition ligand-binding assay revealed that SGA 360 has a higher affinity for the human AHR than SGA 293. This would indicate that the position of the methoxy groups around the phenyl ring has a profound influence on their affinity for the AHR. Nevertheless, both SGA 293 and SGA 360 met the goal of this study to generate useful SAhRMs that fail to interact with the ER.

Cell culture-based studies with Huh7 cells illustrating the suppression of cytokine-mediated inflammatory gene expression (e.g. SAA1) by Way-169916 (22, 31) and SGA 360 clearly demonstrate the anti-inflammatory potential of SAhRMs. However, cell culture-based observations are limited in that they are restricted to a single homogeneous population and thus may not accurately reflect physiological responses. Inflammation is a complex process requiring extensive interplay among numerous cell types; thus, putative anti-inflammatory modulators require in vivo examination. Verification of the anti-inflammatory activity of the SAhRM SGA 360 was demonstrated using the long established TPA-induced ear edema model. Furthermore, $Ahr^{-/-}$ animals, while responsive to TPA, proved to be refractory to the anti-inflammatory activity of SGA 360, thus implicating AHR in its mode of action. While the parent compound Way-169916 can exert suppressive effects upon inflammatory signaling through ER and AHR (22, 31), SGA 360 exhibits minimal ER binding, suggesting that the suppressive action of SGA 360 may be solely mediated through AHR. Pro-inflammatory gene expression (e.g., Cox2 and Il1b) mediated by TPA was markedly repressed by SGA 360. The mechanism of such AHR-dependent repression remains to be elucidated but is likely to involve either protein-protein crosstalk or the ability of a SAhRM to block DRE-mediated AHR

activity. While Cox2 is expressed within the epidermis in response to TPA, the expression of cytokines, e.g., *Illb* and *Il6*, is likely to occur within the epidermis together with resident and infiltrating immune cells. Thus, it is probable that SGA 360 exerts its anti-inflammatory action in multiple cell-types, consistent with previous reports demonstrating a role for AHR in modulating responses to inflammatory stimuli in both skin and immune cells, such as T_H1/2, T_H17, and macrophages (11, 14, 35, 36). It is noteworthy that the efficacy of SGA 360, with regard to inhibition of TPA-induced edematosis, is of the same magnitude as that observed with similar doses of glucocorticoids and nonsteroidal anti-inflammatory drugs (37). The inhibition of inflammation by SAhRM ligands is consistent with previous reports demonstrating a role for the high-affinity Ahr^{b-1} allele in dampening inflammatory signaling in skin following exposure to pro-inflammatory stimuli (36). Such observations may indicate that the production of endogenous AHR ligands capable of limiting inflammatory responses in a SAhRM-like fashion may be produced in vivo. For example, the arachidonic acid derivative, 12(R)-HETE, an activator of AHR can be produced in skin during inflammation and thus could contribute to the regulation of AHR activity in skin cells (38). Interestingly, sustained activation of AHR in keratinocytes promotes inflammatory signaling in mice (39). The contradictory nature of AHR activity is likely to involve inflammatory cytokines (e.g., IL-6, IL-18, and CCL20), which have a DRE-mediated regulatory component (39, 40), and results in elevated expression in response to potent AHR agonists or heightened AHR protein levels. Although these cytokines were not examined in the context of SGA 360 exposure, the inhibition of DRE binding by SAhRMs similar to SGA 360 is likely to suppress such activity and further contribute to its anti-inflammatory profile.

When considering the regulation of AHR-mediated modulation of transcription, it is important to clearly understand differences between a SAhRM and an AHR antagonist and their possible differences in activity, in a particular biological context. For example, if one is interested in blocking a DRE-mediated event such as the induction of CYP1A1, both an antagonist and a SAhRM will exhibit the same apparent inhibitory activity. If the goal were to block all direct AHR-mediated transcriptional modulatory events, an AHR antagonist and a SAhRM would yield very different results. Interestingly, an AHR antagonist is defined in the literature as an AHR ligand that fails to induce a DRE-mediated enhancement of gene expression. This is due to the fact that the AHR was only recently shown to repress gene transcription through protein-protein interactions (20, 41). Thus, whether previously described AHR antagonists are pure antagonists or SAhRMs will require further investigation. An example of these concepts is the activity of α -naphthoflavone (α -NF), which is considered a partial agonist/antagonist and is often used as an antagonist to a full agonist such as TCDD. This flavonoid exhibits a modest ability to induce CYP1A1 mRNA yet is similar to TCDD in its ability, at a relatively high concentration, to inhibit SAA3 expression after cytokine exposure (20). Thus, α -NF exhibits partial agonist/antagonist activity, yet is capable of exhibiting full repression potential.

The potential importance of developing SAhRMs or AHR antagonists is becoming increasingly apparent. At least three specific physiologically important targets modulated by AHR activity have emerged. The first is the ability of the AHR to modulate T cell differentiation and, in particular, their differentiation into $T_{\rm H}17$ cells and an IL22 producing T cell subpopulation that is important in skin (*14, 42*). Studies in cell culture reveal that an AHR antagonist can impair $T_{\rm H}17$ cell

development, suggesting that an AHR antagonist could have therapeutic potential in treating chronic inflammatory diseases (15). The AHR can repress the expression of acute-phase genes, which can be continuously up-regulated during chronic inflammatory diseases such as rheumatoid arthritis. Excessive production of acute-phase gene products such as SAA can lead to enhanced inflammation and amyloidosis; thus, attenuation of the acute phase response in liver would be a second therapeutic target that can be altered by selective activation or antagonism of the AHR. The third possible target is the ability of a SAhRM to inhibit estrogenic activity in breast cancer (43). Most likely, if each of these relevant target diseases were to be treated with an AHR ligand, a SAhRM would be the most logical choice, as an AHR agonist will also modulate DRE-driven AHR transcriptional activity that could lead to toxicity or alter drug metabolism. Future studies are needed to test whether SGA 360 would be effective in treating chronic inflammatory diseases.

Acknowledgment. We thank Dr. Michael Denison for H1L1.1c2 cells and Kelly Wagner for her technical assistance for the *SAA* repression assay. We thank Marcia H. Perdew for editorial assistance. This work was supported by NIEHS, National Institutes of Health Grants ES04869. The NMR instrumentation in this project is funded, in part, under a grant from the Pennsylvania Department of Health using Tobacco Settlement Funds. The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. Additional instrumentation support came from NIH 1 S10 RR021172.

Supporting Information Available: Copies of the ¹H NMR spectra for compounds **1**, **2**, **3**, **4**, **5**, **10**, **11**, **12**, **13**, and **14**; copies of ¹³C NMR spectra (Figures S1 and S2) and partial HMBC spectra (Figures S3 and S4) for compounds **4** and **14**; and Figures S5 and S6 provide additional data demonstrating that SGA 360 does not interact with the ER. This material is available free of charge via the Internet at http://pubs.acs.org.

References

- Gabay, C., and Kushner, I. (1999) Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340, 448–454.
- (2) Cheng, N., He, R., Tian, J., Ye, P. P., and Ye, R. D. (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J. Immunol. 181, 22–26.
- (3) Okamoto, H., Katagiri, Y., Kiire, A., Momohara, S., and Kamatani, N. (2008) Serum amyloid A activates nuclear factor-kappaB in rheumatoid synovial fibroblasts through binding to receptor of advanced glycation end-products. *J. Rheumatol.* 35, 752–756.
- (4) Lee, M. S., Yoo, S. A., Cho, C. S., Suh, P. G., Kim, W. U., and Ryu, S. H. (2006) Serum amyloid A binding to formyl peptide receptorlike 1 induces synovial hyperplasia and angiogenesis. *J. Immunol.* 177, 5585–5594.
- (5) Yan, S. D., Zhu, H., Zhu, A., Golabek, A., Du, H., Roher, A., Yu, J., Soto, C., Schmidt, A. M., Stern, D., and Kindy, M. (2000) Receptordependent cell stress and amyloid accumulation in systemic amyloidosis. *Nat. Med.* 6, 643–651.
- (6) Beischlag, T. V., Luis Morales, J., Hollingshead, B. D., and Perdew, G. H. (2008) The aryl hydrocarbon receptor complex and the control of gene expression. *Crit. Rev. Eukaryotic Gene Expression* 18, 207– 250.
- (7) McMillan, B. J., and Bradfield, C. A. (2007) The aryl hydrocarbon receptor sans xenobiotics: endogenous function in genetic model systems. *Mol. Pharmacol.* 72, 487–498.
- (8) Baba, T., Mimura, J., Nakamura, N., Harada, N., Yamamoto, M., Morohashi, K., and Fujii-Kuriyama, Y. (2005) Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. *Mol. Cell. Biol.* 25, 10040–10051.
- (9) Barnett, K. R., Tomic, D., Gupta, R. K., Miller, K. P., Meachum, S., Paulose, T., and Flaws, J. A. (2007) The aryl hydrocarbon receptor affects mouse ovarian follicle growth via mechanisms involving estradiol regulation and responsiveness. *Biol. Reprod.* 76, 1062–1070.

- (10) Lund, A. K., Agbor, L. N., Zhang, N., Baker, A., Zhao, H., Fink, G. D., Kanagy, N. L., and Walker, M. K. (2008) Loss of the aryl hydrocarbon receptor induces hypoxemia, endothelin-1, and systemic hypertension at modest altitude. *Hypertension* 51, 803–809.
- (11) Negishi, T., Kato, Y., Ooneda, O., Mimura, J., Takada, T., Mochizuki, H., Yamamoto, M., Fujii-Kuriyama, Y., and Furusako, S. (2005) Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J. Immunol. 175, 7348–7356.
- (12) Morales, J. L., Krzeminski, J., Amin, S., and Perdew, G. H. (2008) Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists. *Chem. Res. Toxicol.* 21, 472–482.
- (13) Peck, A., and Mellins, E. D. (2009) Breaking old paradigms: Th17 cells in autoimmune arthritis. *Clin. Immunol.* 132, 295–304.
- (14) Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J. C., and Stockinger, B. (2008) The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. *Nature* 453, 106–109.
- (15) Veldhoen, M., Hirota, K., Christensen, J., O'Garra, A., and Stockinger, B. (2009) Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. *J. Exp. Med.* 206, 43–49.
- (16) Kimura, A., Naka, T., Nohara, K., Fujii-Kuriyama, Y., and Kishimoto, T. (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. *Proc. Natl. Acad. Sci.* U.S.A. 105, 9721–9726.
- (17) Kitamura, M., and Kasai, A. (2007) Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. *Cancer Lett.* 252, 184–194.
- (18) Tian, Y., Ke, S., Denison, M. S., Rabson, A. B., and Gallo, M. A. (1999) Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. *J. Biol. Chem.* 274, 510–515.
- (19) Jensen, B. A., Leeman, R. J., Schlezinger, J. J., and Sherr, D. H. (2003) Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. *Environ. Health* 2, 16.
- (20) Patel, R. D., Murray, I. A., Flaveny, C. A., Kusnadi, A., and Perdew, G. H. (2009) Ah receptor represses acute-phase response gene expression without binding to its cognate response element. *Lab. Invest.* 89, 695–707.
- (21) Bunger, M. K., Glover, E., Moran, S. M., Walisser, J. A., Lahvis, G. P., Hsu, E. L., and Bradfield, C. A. (2008) Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. *Toxicol. Sci. 106*, 83–92.
- (22) Murray, I. A., Morales, J. L., Flaveny, C. A., Dinatale, B. C., Chiaro, C., Gowdahalli, K., Amin, S., and Perdew, G. H. (2010) Evidence for ligand-mediated selective modulation of aryl hydrocarbon receptor activity. *Mol. Pharmacol.* 77, 247–254.
- (23) Steffan, R. J., Matelan, E., Ashwell, M. A., Moore, W. J., Solvibile, W. R., Trybulski, E., Chadwick, C. C., Chippari, S., Kenney, T., Eckert, A., Borges-Marcucci, L., Keith, J. C., Xu, Z., Mosyak, L., and Harnish, D. C. (2004) Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid arthritis. *J. Med. Chem.* 47, 6435– 6438.
- (24) Long, W. P., Pray-Grant, M., Tsai, J. C., and Perdew, G. H. (1998) Protein kinase C activity is required for aryl hydrocarbon receptor pathway-mediated signal transduction. *Mol. Pharmacol.* 53, 691–700.
- (25) Garrison, P. M., Tullis, K., Aarts, J. M., Brouwer, A., Giesy, J. P., and Denison, M. S. (1996) Species-specific recombinant cell lines as bioassay systems for the detection of 2,3,7,8-tetrachlorodibenzo-pdioxin-like chemicals. *Fundam. Appl. Toxicol.* 30, 194–203.
- (26) Poland, A., Glover, E., Ebetino, H., and Kende, A. (1986) Photoaffinity labelling of the Ah receptor. *Food Chem. Toxicol.* 24, 781–787.
- (27) Ramadoss, P., and Perdew, G. H. (2004) Use of 2-azido-3-[1251]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative

ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. *Mol. Pharmacol.* 66, 129–136.

- (28) Flaveny, C. A., Murray, I. A., Chiaro, C. R., and Perdew, G. H. (2009) Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. *Mol. Pharmacol.* 75, 1412–1420.
- (29) Nahm, S., and Weinreb, S. M. (1981) N-methoxy-N-methylamides as effective acylating agents. *Tetrahedron Lett.* 22, 3815–3818.
- (30) De Luca, L., Giacomelli, G., and Taddei, M. (2001) An easy and convenient synthesis of Weinreb amides and hydroxamates. J. Org. Chem. 66, 2534–2537.
- (31) Chadwick, C. C., Chippari, S., Matelan, E., Borges-Marcucci, L., Eckert, A. M., Keith, J. C., Jr., Albert, L. M., Leathurby, Y., Harris, H. A., Bhat, R. A., Ashwell, M., Trybulski, E., Winneker, R. C., Adelman, S. J., Steffan, R. J., and Harnish, D. C. (2005) Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. *Proc. Natl. Acad. Sci. U.S.A. 102*, 2543–2548.
- (32) Zhang, S., Qin, C., and Safe, S. H. (2003) Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. *Environ. Health Perspect.* 111, 1877–1882.
 (33) Schacke, H., Schottelius, A., Docke, W. D., Strehlke, P., Jaroch, S.,
- (33) Schacke, H., Schottelius, A., Docke, W. D., Strehlke, P., Jaroch, S., Schmees, N., Rehwinkel, H., Hennekes, H., and Asadullah, K. (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. *Proc. Natl. Acad. Sci. U.S.A. 101*, 227–232.
- (34) Keith, J. C., Jr., Albert, L. M., Leathurby, Y., Follettie, M., Wang, L., Borges-Marcucci, L., Chadwick, C. C., Steffan, R. J., and Harnish, D. C. (2005) The utility of pathway selective estrogen receptor ligands that inhibit nuclear factor-kappa B transcriptional activity in models of rheumatoid arthritis. *Arthritis Res. Ther.* 7, R427–4R38.
- (35) Shi, L. Z., Faith, N. G., Nakayama, Y., Suresh, M., Steinberg, H., and Czuprynski, C. J. (2007) The aryl hydrocarbon receptor is required for optimal resistance to Listeria monocytogenes infection in mice. *J. Immunol.* 179, 6952–6962.
- (36) De Souza, V. R., Cabrera, W. K., Galvan, A., Ribeiro, O. G., De Franco, M., Vorraro, F., Starobinas, N., Massa, S., Dragani, T. A., and Ibanez, O. M. (2009) Aryl hydrocarbon receptor polymorphism modulates DMBA-induced inflammation and carcinogenesis in phenotypically selected mice. *Int. J. Cancer* 124, 1478–1482.
- (37) De Young, L. M., Kheifets, J. B., Ballaron, S. J., and Young, J. M. (1989) Edema and cell infiltration in the phorbol ester-treated mouse ear are temporally separate and can be differentially modulated by pharmacologic agents. *Agents Actions* 26, 335–341.
- (38) Chiaro, C. R., Patel, R. D., and Perdew, G. H. (2008) 12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid derivative, is an activator of the aryl hydrocarbon receptor. *Mol. Pharmacol.* 74, 1649–1656.
- (39) Tauchi, M., Hida, A., Negishi, T., Katsuoka, F., Noda, S., Mimura, J., Hosoya, T., Yanaka, A., Aburatani, H., Fujii-Kuriyama, Y., Motohashi, H., and Yamamoto, M. (2005) Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions. *Mol. Cell. Biol.* 25, 9360–9368.
- (40) Hollingshead, B. D., Beischlag, T. V., Dinatale, B. C., Ramadoss, P., and Perdew, G. H. (2008) Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. *Cancer Res.* 68, 3609–3617.
- (41) Beischlag, T. V., and Perdew, G. H. (2005) ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J. Biol. Chem. 280, 21607– 21611.
- (42) Trifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K., and Spits, H. (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. *Nat. Immunol.* 10, 864–871.
- (43) Zhang, S., Lei, P., Liu, X., Li, X., Walker, K., Kotha, L., Rowlands, C., and Safe, S. (2009) The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. *Endocr. Relat. Cancer 16*, 835–844.

TX100045H